# A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders

> **NCT00986336** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 56 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** topiramate
- **DRUG:** topiramate
- **DRUG:** risperidone
- **DRUG:** topiramate

## Key facts

- **NCT ID:** NCT00986336
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986336, "A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT00986336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*